Table 1.
Patient characteristics
| MS-275 (dose level) | Age, y | Sex | Diagnosis | Stage of disease | Cytogenetics |
|---|---|---|---|---|---|
| 4 mg/m2 × 2/4 wk (DL 1) | |||||
| Patient 1 | 56 | F | AML, M3 | Refractory relapse 2 | 50XX, t(4;12), t(15;17), +4mar |
| Patient 2 | 69 | M | AML, M2 | Primary refractory | 47XY, 20q−, +11 |
| Patient 3 | 70 | M | AML, M1 | Refractory relapse 1 | 45X, −Y |
| Patient 4 | 72 | M | AML, M7 | Primary refractory | 46XY |
| Patient 5 | 49 | F | AML, M0 | Primary refractory | 45XX, der(2), der(3), −7, −11, −17, der(12), +2mar |
| 6 mg/m2 × 2/4 wk (DL 2) | |||||
| Patient 6 | 44 | F | AML, M4 | Primary refractory | 46X, t(X;7), inv(3) |
| Patient 7 | 85 | M | AML, M5 | Primary refractory | 46XY |
| Patient 8 | 49 | M | CML-BC | Relapse 1 | 46XY, t(9;22), t(15;17) |
| Patient 9 | 65 | F | AML, M5 | Relapse 1 | 46XX |
| Patient 10 | 54 | M | AML, M1 | Refractory relapse 1 | 42XY, −5, −7, +8, +9, inv(12), −16, −17, −17,der(18), −20, −20, −21, +2mar |
| 8 mg/m2 × 2/4 wk (DL 3) | |||||
| Patient 11 | 69 | F | AML, M2 | Refractory relapse 1 | 46XX, 7q- |
| Patient 12 | 50 | F | AML, M5 2° | Relapse 1 | 45X, t(9;11), −7, der(12)t(7;12) |
| Patient 13 | 74 | M | AML, M2 | Primary refractory | 45XY, −7 |
| 8 mg/m2 × 4/6 wk (DL 4) | |||||
| Patient 14 | 36 | F | AML, M4 | Relapse 2 | 47XX, t(4;7), inv(9), inv(16), i(17), +22 |
| Patient 15 | 72 | M | AML, M2 | Primary refractory | 47XY, +8/46XY, 20q- |
| Patient 16 | 86 | M | MDS/AML | Refractory relapse 1 | 46XY |
| Patient 17 | 76 | F | AML, M2 | Refractory relapse 1 | 47XX, 7q-, +11 |
| Patient 18 | 65 | F | AML, M7 | Refractory relapse 1 | 46XX |
| Patient 19 | 45 | M | AML, M4 | Refractory relapse 2 | 46XY, inv(16)/45XY, 7q−, add(8), der(12)t(12;17), der(17)t(12;17)del(17)(q11), −21 |
| Patient 20 | 65 | M | MDS/AML | Primary refractory | 46XY |
| Patient 21 | 66 | M | AML, M0 | Primary refractory | 47XY, +13 |
| Patient 22 | 25 | F | AML, M5 | Refractory relapse 2 | 50XX, t(3;19), +i(5),+8, +8, der(9)t(9;11)del(9), der(11)t(9;11), der(17)t(8;17),+19, +1mar |
| Patient 23 | 63 | F | AML, M5 2° | Refractory relapse 1 | 46XX, inv(3), t(11;22) |
| Patient 24 | 74 | F | MDS/AML | Primary refractory | 47XX, +8 |
| Patient 25 | 57 | M | AML, M4 | Refractory relapse 1 | 48XY, 5q−, +8, +13 |
| Patient 26 | 38 | M | AML, M1 | Primary refractory | 45XY, del(1), add(2), add(3), inv(8), add(9), add(12), der(12), add(13), add(14),der(16)t(16;17), −17, del(17), add(18), −19, der(20)t(9;20), +mar |
| Patient 27 | 73 | M | AUL | New diagnosis | 46X, −Y, t(11;21), +13 |
| Patient 28 | 65 | M | AML, M5 | Refractory relapse 1 | 46XY |
| Patient 29 | 67 | M | MDS/AML | Relapse 1 | 45XY, t(1;9), −7, 20q− |
| 10 mg/m2 × 4/6 wk (DL 5) | |||||
| Patient 30 | 55 | M | MDS/AML | Refractory relapse 1 | 47XY, inv(1), t(10:15), 13q−, +21 |
| Patient 31 | 73 | M | AML, M6 | Primary refractory | 42-51XY, 7q−, der(11), −12, −17, −18, add(19), t(12;20), +3-5mar |
| Patient 32 | 57 | M | AML, M4 | Primary refractory | 45XY, add(3), add(4), −5, 7q−, add(10), −12, add(13), del(16), −17, +2mar |
| Patient 33 | 70 | M | MDS/AML | Primary refractory | 46XY |
| Patient 34 | 72 | M | MDS/AML | Primary refractory | 48XY, +13, +21 |
| Patient 35 | 55 | M | AML, M4 | Refractory relapse 1 | 46XY |
| Patient 36 | 67 | M | AML, M5 | Relapse 1 | 48XY, +5, +7 |
| Patient 37 | 60 | M | AML, M7 | Primary refractory | 46XY, −1, add(1), del(2), add(3), add(5), −6, del(6), −7, del(8), del(10), del(12), add(15), add(16), add(17), del(18), +1-3mar |
| Patient 38 | 72 | M | MDS/AML | Primary refractory | 47XY, dup(4), dup(7), +8 |
| Patient 39 | 52 | F | MDS/AML | Primary refractory | 47XY, +8 |
AML indicates acute myeloid leukemia; CML-BC, chronic myeloid leukemia-blast crisis; AUL, acute undifferentiated leukemia; 2°, secondary; MDS/AML, AML arising from myelodysplasia.